pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
Regiocit solution pour hémofiltration
Approved · small molecule · Adult patients hospitalized in intensive care with an indication of EER with ARC during the stay.
Regiocit solution pour hémofiltration for Adult patients hospitalized in intensive care with an indication of EER with ARC during the stay. is a Approved program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP220257
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Adult patients hospitalized in intensive care with an indication of EER with ARC during the stay.
- Status
- active
- Trials
- 1